Leadership

Mark L. Baum is the founder, Chairman of the Board, and Chief Executive Officer of Harrow. Mr. Baum is a founder and former board member of Eton Pharmaceuticals (Nasdaq: ETON) and Surface Ophthalmics, as well as a founder and the current Chairman of the Board of Melt Pharmaceuticals. From 2014-2017, Mr. Baum was a senior advisor to Curology.com. Before Harrow, as the founder of TBLF, LLC, a private investment fund manager, Mr. Baum made more than 200 investments in, and provided advisory and board service to, more than 40 private and public companies. In 1999, Mr. Baum founded YesRx, an HIV-focused pharmacy business. Mr. Baum actively advocates for patient and physician pharmaceutical accessibility issues, including being featured in Op-Ed contributions for the Wall Street Journal and appearances on national and international media outlets and other forums. Mr. Baum was named by Ernst & Young LLP as the 2017 Entrepreneur of the Year™ in the life sciences category for the San Diego region. Mr. Baum serves on the board of the Ophthalmology Foundation, which works with eye care professionals and professional societies to enhance and provide ophthalmic education, focusing on low-resource and underserved countries. Mr. Baum is a graduate, cum laude, of The University of Texas at Arlington and a 1997 graduate of California Western School of Law.

Andrew R. Boll, a founding employee of Harrow, serves as President, Chief Financial Officer and Corporate Secretary, overseeing the Company’s financial, market access and administrative operations. Mr. Boll also co‑founded Eton Pharmaceuticals (Nasdaq: ETON), Melt Pharmaceuticals, Surface Ophthalmics, and ImprimisRx. Before joining Harrow, he managed accounting, financial analysis, and reporting for an investment company from 2007 to 2011, and he was also heavily involved with the financial operations of a number of the fund’s portfolio companies (public and private). Prior to 2007, Mr. Boll held various accounting roles at Welsh Companies, a commercial real estate company, its fund and its other subsidiaries. Mr. Boll is a CFA® charterholder, a Certified Management Accountant (CMA®), and graduatedsumma cum laude with a Bachelor of Science in Corporate and Public Finance.

Amir H. Shojaei was named Harrow’s Chief Scientific Officer in January 2025, bringing with him nearly 30 years of experience in the life sciences sector. A recognized leader in clinical development, regulatory affairs, and the commercialization of biopharmaceutical and biologic products, Dr. Shojaei oversees Harrow’s medical and clinical affairs, regulatory affairs, pharmacovigilance and QA/compliance for FDA-approved products. Throughout his career, Dr. Shojaei has been instrumental in the advancement of innovative treatments for anterior and posterior segment eye diseases. Notable, he led the development and FDA approval of Xiidra®, a groundbreaking therapy and the first product to treat both the signs and symptoms of dry eye disease. Prior to joining Harrow, he held senior leadership roles at several prominent biopharmaceutical companies, including AsclepiX Therapeutics, TherOptix, Novartis Pharmaceuticals, and Shire Pharmaceuticals (acquired by Takeda). Dr. Shojaei holds a Pharm.D. and Ph.D. from the University of the Pacific. In addition, he is the holder of multiple patents and has authored over 25 peer-reviewed publications.

Michael D. Biega has served as Harrow’s Vice President of Investor Relations and Communications since June 2025. Michael is a seasoned investor relations and communications executive with nearly 15 years of experience in the healthcare sector. He most recently served as Senior Director, Head of Investor Relations at Sensei Biotherapeutics, a clinical-stage oncology company, where he built and led the investor relations and corporate communications function. Before joining Sensei, Mike was a Managing Director at Solebury Trout (formerly The Trout Group), a premier investor relations and strategic advisory firm. As a key member of the leadership team, he advised numerous public and private biotech companies on investor relations strategy, corporate messaging, and capital markets positioning. Mike began his career on the equity sales desk at Summer Street Research Partners, a biotech-focused investment bank where he was responsible for distributing healthcare equity research to institutional investors. He holds a Bachelor of Arts in Economics from Harvard University, where he was a four-year member of the men’s ice hockey team.

Prashanth S. Annavajjhala joined Harrow in September 2023, and has served as Harrow’s Chief of Staff since July 2025. Prashanth has over 10 years of experience in Market Access, Healthcare Strategy, and Product Commercialization within the pharmaceutical industry. He has a strong background in ophthalmology, including product launches and market positioning strategies. Dr. Annavajjhala has a proven track record of developing corporate strategies and leading cross-functional teams at organizations such as Regeneron and Enventure. He completed his medical education in India and later moved to the United States for higher studies. He holds an M.D. degree and an MBA from Rice University.

Patrick W. Sullivan joined Harrow as Head of Commercial in August 2025, bringing 25 years of commercial leadership experience across U.S. and global markets. A proven strategist and operator, he has deep expertise in commercialization planning, launch strategy, market development, go-to-market execution, and growth acceleration in specialty, rare, and complex diseases. His experience spans emerging biotechs, mid-sized firms, and global pharma. Before joining Harrow, Mr. Sullivan was Vice President of Marketing, Neurology Portfolio at Corium Therapeutics, where he led U.S. commercialization and launches in ADHD and dementia. Under his leadership, Azstarys® became the fastest-growing ADHD treatment, while Adlarity® introduced a novel transdermal delivery technology of Donepezil for Alzheimer’s disease. Previously, he served as Global Commercial Head and Executive Director at AstraZeneca, directing the launch of Evrenzo® (roxadustat), a first-in-class anemia therapy. This launch marked an industry milestone as the first novel MOA to debut in China ahead of the U.S. or EU, and Mr. Sullivan partnered with development teams to advance multiple new indications. Earlier in his career, he held leadership roles at Shire, Adolor, Novartis, and Bayer, consistently exceeding performance goals and earning multiple team and individual awards. Mr. Sullivan holds a B.S. in Business Administration from Widener University and is pursuing an Executive MBA in Healthcare Marketing at Saint Joseph’s University.

Frank W. Mullery serves as President and Chief Executive Officer of Harrow’s ImprimisRx Division. With over 20 years of leadership experience in the healthcare and pharmaceutical sectors, he has built and scaled businesses, launched market-shaping products, and driven transformative growth. Most recently, he served as President of Sintetica US, where he spearheaded the creation of the company’s U.S subsidiary – taking it from concept to full commercialization, while successfully launching its first five sterile injectable products. Previously, he served as President and Chief Commercial Officer of STI Pharma, where he oversaw all company operations, revitalized its strategy with a five-year growth plan, and launched several sterile injectable products. Prior to STI, he spent more than seven years at Mylan, culminating in his role as President of Mylan Institutional, where he established Mylan Institutional as a key player in the U.S. sterile injectable market. Under his leadership, revenues grew to more than $1 billion in 2018, launched its first U.S. biosimilar (Fulphila), introduced over 20 sterile injectable products in a single year, and established strong relationships with key customers. Mr. Mullery also held senior finance leadership roles at Mylan, including CFO of North America and CFO of Mylan Pharmaceuticals Inc., where he helped guide the company’s flagship generics division. He holds an Executive MBA from Villanova University and a bachelor’s degree in Accounting from King’s College.